VIDEO: Implanet CEO Ludovic Lastennet Interviewed in OTCQX Video Series

NEW YORK, Jan. 11, 2017

In the interview, Ludovic Lastennet discusses:

• Implanet's key product, JAZZ, a disruptive technology that replaces the traditional implant used in spinal surgeries. 
• How trading on OTCQX is reflective of Implanet's goal to reach U.S. investors. As a part of this effort, the company has taken an active role in attending conferences and roadshow meetings
• With 16,000 JAZZ implants already in use in 3,000 patients, the company discussed their growth outlook for 2017

To watch the complete interview, visit OTC Markets Group's YouTube page at https://youtu.be/ExZPaBVrYa4

Implanet is a medical technology company based in France, with a U.S. office in Boston. The Company is engaged in the manufacturing, marketing and commercial development of implants and medical devices used in orthopedic surgery. The Company's product range covers knee surgery with a full range of total knee prosthesis and sport medicine implants. The Company's flagship product, the JAZZ technology platform, provides immobilization and fusion of spinal segments in the reduction of large deformities as well as the treatment of aging population. JAZZ is an adjunct to fusion implant of cervical, thoracic and lumbar spine.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.